GPhA Supports FDA Proposed Rule on E-labeling
A statement from GPhA’s president expresses the organization’s support of FDA’s proposed rule to amend labeling regulations.
In a statement released on Dec. 17, 2014, Generic Pharmaceutical Association (GPhA) President Ralph G. Neas expresses the organization’s support for FDA’s proposed rule to amend prescription drug labeling regulations to require electronic distribution of the prescribing information intended for healthcare professionals. Neas believes the proposed rule would reduce prescribing errors and decrease storage, shipping, and printing costs.
“The proposed rule takes steps to ensure that prescribing information, which is currently delivered to health professionals in paper format, is distributed electronically. This information could include critical details necessary for effective use of the product or timely updates to safety information,” says Neas in the statement. “…e-labeling gives prescribers and dispensers immediate access to the most current, FDA-approved drug prescribing information. This means that manufacturers can provide electronic updates to labels in weeks, rather than the months, or even years.”
Drug Solutions Podcast: A Closer Look at mRNA in Oncology and Vaccines
April 30th 2024In this episode fo the Drug Solutions Podcast, etherna’s vice-president of Technology and Innovation, Stefaan De Koker, discusses the merits and challenges of using mRNA as the foundation for therapeutics in oncology as well as for vaccines.
Drug Solutions Podcast: Gliding Through the Ins and Outs of the Pharma Supply Chain
November 14th 2023In this episode of the Drug Solutions podcast, Jill Murphy, former editor, speaks with Bourji Mourad, partnership director at ThermoSafe, about the supply chain in the pharmaceutical industry, specifically related to packaging, pharma air freight, and the pressure on suppliers with post-COVID-19 changes on delivery.
Pharmaceutical Tariffs Are Imminent: How Industry is Bracing for Impact
April 16th 2025On April 14, 2025, the Trump Administration launched a national security-driven investigation into pharmaceuticals, a move that will likely result in tariffs being placed on pharmaceutical drugs, ingredients, and other components that are imported from outside of the United States.
